This website contains information intended only for persons professionally dealing with medical devices (e.g. for persons performing medical professions, for persons dealing with the distribution of medical devices). Please confirm that you are a medical device professional to proceed.

Targeted diagnostic precision

Cardiolens FFR-CT Pro® Diagnostic Test

At Hemolens Diagnostics, we have developed a non-invasive method of diagnosing coronary artery disease with the help of FFR-CT. Cardiolens FFR-CT Pro® combines two non-invasive diagnostic tools: Coronary Computed Tomography Angiography (CCTA) and Continuous Non-invasive Blood Pressure (CNBP).  In combination with computational fluid dynamic principles, these data are used to generate a 3D model of the blood vessels, allowing for a detailed anatomical and functional evaluation of coronary arteries. This information allows the overseeing physician to better evaluate stenosis severity and thereby plan appropriate treatment or follow-up.

Hemolens Diagnostics follows the unstoppable trend of the digitalization of medicine. Drawing from computational fluid dynamics algorithms, this technology can be applied in the future to numerous other disciplines including oncology, pulmonology, angiology or neurology. It could soon become the gold standard around the globe.

Expected benefits of Cardiolens FFR-CT Pro® diagnostic test

  • Outpatient diagnostics based on the anatomical and functional evaluation of coronary arteries, with no need for hospitalization
  • Capable of generating patient-specific 3D anatomical models of coronary arteries that provide insight into the functional severity of the existing stenoses and blood flow obstructions. This allows for better standardization of evaluation at the CCTA level. With 3D modeling, physicians can easily show and successfully explain the results to their patients 
  • Personalized imaging and 3d modeling of coronary arteries 
  • Valuable to standardize the care of chronic coronary syndrome patients who get a CCTA scan
  • Reduces the need for invasive testing procedures
  • Suitable for patients who have contraindications to coronary angiography
  • Convenience and usability – log in to the Cardiolens FFR-CT Pro® platform

Recommendations and guidelines

ESC 2019

ESC – European Society of Cardiology

2019 ESC Guidelines for the Diagnosis and Management of Chronic Coronary Syndromes.

ACC/AHA 2021

American Heart Association

2014 ACC/AHA/AATS/PCNA/SCAI/STS Focused Update of the Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease.

Frequently Asked Questions

How is the FFR-CT result calculated with Cardiolens FFR-CT Pro®?

The FFR-CT measurement and 3D coronary models are obtained using computational fluid dynamics algorithms. Coronary CT angiography (CCTA) and continuous non-invasive blood pressure (CNBP) measurements from each patient are used as the basis input for these algorithms to generate accurate patient specific simulations of their coronary artery network.

How is the FFR-CT measurement visualized?

The physician receives the test results in the form of a 3D image of the coronary vasculature, with anatomically significant stenoses flagged. Pointing to a given stenosis displays the relevant calculated FFR-CT parameter.

Collaborating Sites

National Institute of Cardiology Stefan Cardinal Wyszynski - National Research Institute

Military Clinical Hospital with Polyclinic

T. Marciniak Lower Silesia Specialized Hospital - Center of Emergency Medicine

Prof. Leszek Giec Upper Silesia Medical Center of the Silesian Medical University

Clinical Center at Medical University

JPII Cracow Specialized Hospital

Jan Mikulicz-Radecki University Clinical Hospital

Polish-American Heart Clinics

Polish-American Heart Clinics

University Hospital in Cracow

Physicians Perspective

MD Michal Sobanski

University Clinical Hospital - Wroclaw, Poland

I believe that together with Hemolens Diagnostics we will create a new standard that will enable non-invasive FFR-CT diagnostics in patients with intermediate-risk coronary artery disease. This is for those who, due to contraindications, would not get this diagnosis by invasive means.

MD, PhD Cezary Kepka

National Institute of Cardiology - Anin, Poland

Hemolens Diagnostics, using FFR-CT, offers and is developing a novel and promising technology for the detection of anatomically and functionally significant coronary artery stenosis based on non-invasive testing: coronary computed tomography angiography (CCTA) and continuous non-invasive blood pressure (CNBP). Methods based on determination of the fractional flow reserve (FFR) from computed tomography of the coronary arteries are recommended by international scientific societies.

MD Adrian Korbecki

University Clinical Hospital - Wroclaw, Poland

I became involved in the Hemolens Diagnostics collaboration because I believe that with advanced technology, we can push the boundaries of current diagnostic procedures and provide increasingly precise information for clinical practice. Non- invasive testing is the foundation of the medicine of the future.